Abstract
BackgroundHepatitis B virus (HBV) is one of the most prevalent and serious infections worldwide. HBV reactivation is a serious complication for lymphoma patients who are being treated with rituximab-containing regimen. Since the impact of HBV has not been fully evaluated on the prognosis of diffuse large B cell lymphoma (DLBCL), this study examined the effect of the hepatitis infection on the progression-free survival (PFS) and overall survival (OS) in patients with DLBCL who received rituximab-containing chemotherapy.MethodsThis retrospective cohort study was conducted at Princess Noorah Oncology Center, Jeddah by reviewing all medical records of 172 DLBCL diagnosed patients and recieved Rituximab-containing chemotherapy dated from January 2009 to February 2016.ResultsOut of 172 patients, 53 were found positive in hepatitis serology. The 12 of those were HBsAg-positive and 41 were HBcAb-positive. Hepatitis reactivation was observed in 1% of the patients (i.e., 2 out of 172) and both of them were HBsAg-positive. Thus, the risk of hepatitis reactivation among the HBsAg-positive patients was 17% (i.e., 2 out of 12). The predicted 3-year PFS for HBsAg-positive and HBcAb-positive were 52% (± 8%), while 76% (± 4) for HBsAg-negative and HBcAb-negative patients. On the other hand, the predicted 3-year OS for HBsAg and HBcAb-negative group is 93% (±3) while for HBsAg-positive and HBcAb-positive is 77% (±7), respectively.ConclusionThe present study demonstrated a low HBV reactivation rate of 1% exclusively in 2 patients with HBsAg-positive status diagnosed with DLBCL and receiving R-CHOP chemotherapy.
Highlights
Hepatitis B virus (HBV) is one of the most prevalent and serious infections worldwide
hepatitis B surface-antigen (HBsAg)-positive status diagnosed with diffuse large B cell lymphoma (DLBCL) and receiving R-CHOP chemotherapy
HBV reactivation is a serious complication for lymphoma patients who are being treated with rituximab containing regimen [3,4,5]
Summary
Hepatitis B virus (HBV) is one of the most prevalent and serious infections worldwide. Since the impact of HBV has not been fully evaluated on the prognosis of diffuse large B cell lymphoma (DLBCL), this study examined the effect of the hepatitis infection on the progression-free survival (PFS) and overall survival (OS) in patients with DLBCL who received rituximab-containing chemotherapy. Sciences (KSAU-HS), Jeddah, Saudi Arabia is approximately 2 to 20% for HBcAb-positive patients [6,7,8]. While the risk of reactivation and the role of prophylactic antiviral were described in the literature, the impact of HBsAg-positive or HBcAb-positive status on the DLBCL prognosis has not been fully evaluated. This study examined the effect of hepatitis infection on the progression-free survival (PFS) and overall survival (OS) in patients with
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have